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Abstract
Peripheral intravenous catheters (PIVC) are used in high volume in acute and ambulatory
settings. Due to high volume of use in patient care, complications from a PIVC can
significantly impact patient experience. Literature indicates complications such as blood
exposure, phlebitis, unplanned removal, infiltration, occlusion, dwell time, pain, and cost
have serious consequences in patient care, leading to potential delays in treatment, patient
discomfort, patient dissatisfaction, safety concerns, nursing interruptions, increased length of
stay, and added costs. Gap analysis indicates additional research can prove beneficial for
evidence-based care improvement. The authors propose using the plan, do, study, act to
conduct a feasibility study of a multi-center, randomized-controlled trial (RCT), evaluating
three different PIVC systems to compare outcomes. The purpose of this pilot was to

determine the feasibility of assessing nurse and patient outcomes related to the use of
three different types of PIVC, and to pilot implementation of a RCT prior to the
expansion of the study to other facilities, which comparatively evaluated outcomes
between two closed PIVC systems and an open PIVC system.
Keywords: intravenous catheter, randomized control trial, intravenous complications,
PDSA, feasibility, closed PIVC, open PIVC, phlebitis
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Introduction
On June 16, 2015, a 238-bed community hospital in the mid-Atlantic state
changed products for peripheral intravenous catheters (PIVC) and began using the system
product for the purpose of standardization of both product and practice. This facility was
using a PIVC for over 20 years; an all in one closed-system device. The standardized
product for the hospital system was an open-system device.
The Quality and Patient Safety Department (QPS) at the pilot site began receiving
staff event reports and patient comment cards related to the new PIVC (G. Yost, personal
communication, June 18, 2015). Patient comment cards were available in all outpatient
areas as well as main lobbies throughout the hospital. Inpatient hospital consumer
perception of providers and systems comments were submitted by patients. The majority
of the submitted patient comment cards were from outpatient locations, including the
Cancer Center, Treatment Center, and Outpatient Surgery units. Patients with
reoccurring visits to these units shared their experience with the new PIVC compared to
their experience with the previous product. The comments were reviewed and several of
the themes that emerged from patients were: painful insertions, pain during dwell time,
blood leakage (during insertion), multiple insertion attempts, and frequent PIVC
replacement. Staff also began expressing concerns. The top immediate concerns
reported by staff included blood exposure risk, multiple insertion attempts, and painful
insertion reports from patients. Other staff concerns included kinking catheters, sheared
catheter tips, tubing disconnects, leaking sites, PIVCs falling out, and continued pain
during PIVC dwell time. There had been one needle-stick and one staff mucocutaneous
blood exposure reported by Occupational Health related to the new catheters, compared
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to no previously reported needle-sticks or exposures related to the previous PIVC, in the
previous year (G. Yost, personal communication, June 18, 2015). By December 2015, the
QPS department had received a total of 551 reported issues and 102 patient comment
cards related to the PIVC product change.
In response to the feedback on the new product requiring additional sticks to
obtain PIVC access, a data analysis of the mean number of PIVC insertion attempts was
conducted. This provided establishment of a quantitative metric to evaluate. The data
source was the electronic health record (EHR), PIVC insertion attempts, and
documentation for PIVC therapy. Data included Emergency Department (ED), Cancer
Center, Treatment Center, and inpatient patients. A retrospective data review of PIVC
attempts from the timeframe of April 13 – June 15, 2015 was compared to the postchange timeframe of July 29 – September 30, 2015. Six weeks of data was purposely
removed during the timeframe of June 16 – July 28, 2015 to account for the expected
learning curve with the new product. Figure 1. displays the pre-mean and post-mean data
of PIVC insertion attempts.
A two-sample t-test concluded that the mean PIVC attempts for the new PIVC
was statistically significantly greater than the mean PIVC attempts of the previous PIVC
with a p-value of <0.001. A two-sample standard deviation test concluded that the
standard deviation of PIVC attempts for the new product was statistically significantly
greater than the standard deviation of PIVC attempts of the previous product (closed
PIVC system 1) with a p-value of <0.001. A two-sample % defective test with a defect
defined as a PIVC attempt >1 concluded that the number of defects for the new product
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was statistically significantly greater than the number of defects for the previous product
with a p-value of <0.001.

Figure 1. Mean PIVC attempts by month.
After evaluating the influx of comment cards reporting reduced patient and staff
satisfaction, as well as evaluating the increased number of attempts required with the new
PIVC, continued reporting of opportunities for improvement (OFI) reports occurred; even
though, standard onsite training occurred. When OFI reports initially began, the facility
immediately reached out to the other hospitals within their health system; however, no
other hospitals were reporting similar events. Additionally, their patient comments did
not reflect any dissatisfaction with the standardized PIVC a PIVC system the other eleven
hospitals had been using for greater than 20 years. Senior Leadership then authorized
additional training and coaching on insertion technique, which was conducted over two
weeks, to evaluate whether problems reported and dissatisfaction were related to user
error versus the PIVC itself. A representative from the vendor returned onsite in the fall
of 2015 to initiate re-training and re-education for nurses, specifically on procedure and
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technique. Safety reports and dissatisfaction continued to be reported. While numbers of
nursing complaints began to drop, patient complaints continued (G.Yost, personal
communication, July 29, 2016).
Cost was an additional concern. A detailed cost analysis was performed by the
QPS Department, comparing the total cost of the previous closed-system versus the
current open-system. The cost of the previous PIVC system included a closed system
with the added option of a power-injectable product for PIVC situations in which a larger
gauge is necessary for high flow. Twelve months of usage data for both previous
products was obtained. Usage data for the new open-system was evaluated during the
timeframe of August 2015 – November 2015, purposely excluding usage data during the
first 2 months of start-up. Add on extension sets and clave usage was included in the
analysis for both systems to account for the increase in add-on device expense with the
use of the open-system without a built in extension set. An average daily cost for addons was calculated by taking the total number of add-on items and dividing by the total
cost of add-on items for the above timeframes. The PIVC dressing usage and cost was
included for both systems due to a change of product and increase in cost for the current
system relative to the need for a more advanced securement dressing for the open-system.
The cost and usage of an absorbent towel was included in the cost of the current system.
This was an added product to the PIVC start kit due to blood leakage with an opensystem. All usage and cost data were obtained from the materials management
department and was rate adjusted to account for patient days. The daily usage and cost
for each product were multiplied for a per day cost. The cost per day was extrapolated
into a per month and a per year cost. The cost per year of the current open-system was
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calculated at $573,262. The per year cost of the previous closed-system was calculated at
$469,963. Inpatient census and outpatient encounters were evaluated and compared for
both system timeframes to eliminate concerns of increased usage due to patient volume.
The estimated 3% increase in patient volume could produce at most a $14,000 cost
variance. This leaves an estimated $89,000 increase in the current open-system (G. Yost,
personal communication, June 18, 2015). The analysis shows that the new open-system
is more costly than the closed-system and that comparing the cost of only the PIVC fails
to produce an accurate evaluation of total cost incurred when switching from a closed to
an open system. The increase in cost can be primarily attributed to the increase in usage
of add-on products along with the more advanced securement dressing and the added
absorbent towel. Other indirect costs for analysis were excluded, such as bed linens,
towels, gauze, scrubs, etc. Additionally, nursing time was excluded from this calculation,
which, as indicated by an increased number of insertion attempts related to the new PIVC
system, would also be increased. In conclusion, there are additional costs with the opensystem some of which are not accounted for in this analysis.
Review of Literature
As issues remained in the clinical setting and re-training was completed, nurse
leaders turned to the literature for further perspectives and guidance on types of PIVCs.
A literature review was completed to establish the current available research related to
open verses closed PIVCs and a table of evidence was compiled (Appendix I). Three
randomized controlled trials (RCT) were available for review, indicating a need for
continued research in this area of interest. A 2013 RCT with the aim to compare closedsystem with open-system PIVCs, showed an increase in dwell time, a 29% decrease in
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phlebitis rates and a 20% relative risk reduction of catheter-related infections with a
closed-system (González López et al., 2013). A 2014 RCT compared an integrated
closed-system with a built in stabilization platform to a conventional catheter with a
blood control valve. This study concluded that there were significantly fewer catheter
replacements due to catheter related complications in the integrated closed-system and
that the pre-attached wing-shaped stabilization platform was the main contributor to this
result (Tamura et al., 2014). The results from this study also suggested that longer dwell
times offset the higher initial catheter costs of a closed-system. Bausone-Gazda,
Lefaiver, & Walters (2010), conducted a RCT at a level one trauma, American Nurses
Credentialing Center (ANCC) Magnet® designated, facility comparing a closed-system
with a built in stabilization platform to an open-system catheter in which an add-on
stabilization device was applied. This study concluded that the risk of securement related
complications was reduced by 26% in the closed-system with the built in stabilization
device, and findings were utilized to support the Infusion Nursing Standards of Practice
for catheter stabilization (Bausone-Gazda, Lefaiver, & Walters, 2010). All three studies
found evidence of benefit by utilizing a closed versus open PIVC system.
Blood exposure risk was a prominent concern for clinical staff and these concerns
continued past the six week learning time period. Even after additional on-site PIVC
insertion training, staff continued to report inability to occlude the vessel and prevent
blood leakage during insertion for certain patients. A 2011 quantitative study focused on
reducing blood exposure risk and cost associated with PIVC insertion (Richardson &
Kaufman, 2011). In this study, when surveyed about traditional open-system PIVCs,
49% of nurses reported blood exposure 50% of the time; 20% stated they experienced
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blood leakage 100% of the time; 10% stated they never experienced blood leakage
(Richardson & Kaufman, 2011). Comparatively, nurses reported blood exposure 11% of
the time with closed-system PIVCs (Richardson & Kaufman, 2011). In this same study,
when asked about blood leakage onto scrubs, 50% of nurses who had blood leak onto
their scrubs stated that they changed immediately; the other 50% attempted to clean up
the blood from their scrubs. This study also highlighted research related to under
reporting of blood exposure, stating in the United States, researchers have found this rate
to be as high as 82% (Richardson & Kaufman, 2011).
Purpose Statement
The purpose of this pilot was to determine the feasibility of assessing nurse and
patient outcomes related to the use of three different types of PIVC, and to pilot
implementation of a RCT prior to the expansion of the study to other facilities, which
comparatively evaluated outcomes between two closed PIVC systems, and an open
peripheral intravenous system. The open PIVC system was the current standard of care at
the pilot facility. The rationale for including the two closed PIVC systems in this study
was that pilot facility had been using closed PIVC system 1 for over 20 years with no
significant patient complaints or poor patient outcomes as described previously. It was
also important to include a second closed PIVC system in the study. Closed PIVC
system 2is the second generation to the closed PIVC system 1 and it has added power
injectable capability, meaning it is able to support high-pressure injections up to 300psi; a
requirement for injection of dye for computerized axial tomography (CAT) scans. The
Shared Governance Council was involved in the decision and the council recommended
that the closed PIVC system 2 be evaluated for effectiveness as well.
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Variables studied were PIVC dwell time, blood exposure at insertion,
effectiveness of insertion (flashback visualization, number of attempts), pain, needle-stick
prevention feature, complications (phlebitis, dislodgment, infiltration, unintended
removal), cost (device, add-on’s and other applicable materials including clean up
supplies), nurse satisfaction and patient satisfaction.
Problem Statement
PIVCs are used at a high volume in both the acute and ambulatory settings
throughout acute care facilities. Due to the high volume of use and significance in patient
care, failure and/or complications from a PIVC can have a significant impact. Quality
improvement analysis, along with the literature review, indicated that complications such
as infiltration, leaking, pain, phlebitis, reinsertions can have serious consequences in
patient care, leading to potential delays in treatment, patient discomfort, patient
dissatisfaction, safety concerns, nursing interruptions, increased length of stay, morbidity,
and added costs (Bausone-Gazda, Leaiver, & Walters, 2010; Rickard et al., 2015). In a
2015 abstract for a three year RCT underway at a multi-center facility, the primary
investigator (PI) explains that if PIVC failure rates can be reduced by 10%, this could
prevent more than 30 million failures and reinsertions in the United States alone which
would result in reductions in cost, nursing time, and improved patient experiences
(Rickard et al., 2015). Additional research in this area can prove beneficial for evidencebased care improvement within the larger healthcare system, comprised of 11 other
hospitals, and across the nation. Researchers are proposing to conduct a pilot of multicenter RCT to evaluate 3 different PIVCs with the purpose of comparing complications,
blood exposure, nurse and patient satisfaction and potential cost implications. In order to
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evaluate feasibility of such a study, evaluation of specific process measures was
necessary.
Objectives and Aims
The purpose of this pilot was to determine the feasibility of assessing nurse and
patient outcomes related to the use of three different types of PIVC, and to pilot
implementation of a RCT prior to the expansion of the study to other facilities, which
comparatively evaluated outcomes between the closed PIVC system 1 and closed PIVC
system 2,, and the open PIVC system. The results of this pilot have informed the
expansion of this study to a RCT multi-site design. Both process and outcome variables
were collected in this pilot study. In relation to process, the following variables were
studied: response rates, percentage of completed questionnaires, missing data elements,
Clinician Training, feedback from clinician training, enrollment participation, and
preliminary costs. The specific aims were as follows:
1. To examine feasibility of measuring the following items listed, by measuring the:
a.

Clinician and Patient Questionnaire response rate

b. Percentage of Clinician and Patient Questionnaires that are complete
b. Number of missing data elements for each study variable (i.e. number of
data elements missing from electronic chart documentation and items on
questionnaires)
2. Describe clinician training completion by the number of completed Clinician
Training Forms
3. Describe themes in clinician evaluative comments about study training
4. Describe themes in patient comments about PIVC insertion
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5. Describe enrollment participation by measuring the percent of patients declining
to provide consent
6.

Describe preliminary costs by calculating the number of products used at the time
of insertion multiplied by product cost.
Guiding Framework (Theoretical Model)
Utilizing the Institute for Healthcare Improvement (IHI) (2016) test of change

model, the plan, do, study, act cycle (PDSA cycle), a process evaluation was completed
as part of the feasibility of the larger RCT study (Appendix J). The PDSA cycle is a tool
and model used to direct quality improvement measures. The PDSA is a framework used
to plan improvements, test the change, study results, and act on findings (IHI, 2016).
Quality improvement (QI) and process evaluation are important to the RCT due to few
publications and limited knowledge of variables being studied. Appendix H depicts the
research conceptual model for the larger RCT. The PDSA model allowed for iterations to
process as needed, as the RCT expanded to other sites, building on lessons learned from
the feasibility study at the pilot study site. Using the PDSA cycle as part of the feasibility
to the RCT study identified process specific problems (Bowen et al., 2009).
During the planning phase, a workgroup with representation from all RCT
facilities, alongside the research team, began meeting to discuss the development of the
study, including design, study variables, and outcomes. This group continued to meet
weekly to develop education, communication, and clarify details of the project.
Implementing the feasibility study site was the second phase of the PDSA cycle, where
feasibility study outcomes (clinician and patient questionnaire response rate and
percentage of complete questionnaires, number of missing data elements and completed
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clinician training forms, thematic feedback from clinicians and patients, enrollment
participation, and preliminary costs) were collected for evaluation and analysis. Analysis
of these process measure outcomes helped guide expanding this study to the remaining
study facilities, which was the third phase of the PDSA cycle. Finally, evaluating the
findings and making adjustments to any processes within the study, as indicated, was the
last step of the PDSA cycle.
Specific areas of process measure evaluation evaluated were acceptability (to
what extent the process was appropriate), demand (to what extent the process was used),
implementation (to what extent the process was delivered to participants), and practicality
(to what extent this process was being carried out) (Bowen et al., 2009). After IRB
approval and initiation of the project, data collected at the pilot study site was analyzed
and studied, and used to refine processes that were expanded upon at the other RCT
facilities.
Methods (Project and Study Design)
Setting & Resources
Using the PDSA cycle, process measures were evaluated, culminating in an
experimental randomized controlled clinical trial (RCT). A 238-bed community hospital
served as the pilot facility, with the first four weeks of the RCT comprising the data
collection period for this pilot. A PIVC workgroup met weekly and was comprised of
representatives from Quality, Risk & Legal, Nursing, Performance Improvement, Process
Improvement, Data Analytics, and IV Therapy. The PDSA do and study phases of the
change cycle included four-week data collection period that began after completion of
clinician training at the pilot facility. Three PIVCs were studied, with the comparison
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group being the open PIVC system. The intervention groups were the closed PIVC
system 1 with the open PIVC system and closed PIVC system 2 with the open PIVC
system.
Study Population
Participants were selected on a convenience basis from the inpatient and
outpatient population based on the eligibility inclusion and exclusion criteria listed in
Table 1. The number of enrolled patients after four weeks of data collection served as the
pilot study population. The goal was to collect a total of 120 patients (40 enrolled
patients for each PIVC) by the end of four weeks.
Table 1. Inclusion and Exclusion Criteria.
Inclusion Criteria






Inpatients or Outpatients ≥ 18 years old
Available insertion site on the
hand/forearm
Demonstrates cooperation with medical
devices and/or treatments
Speaks and reads English
Able to give Informed Consent

Exclusion Criteria


Participating in another study or previously
participated in this current study



New PIVC site will be placed below an old
infusion site or at an area of flexion



Has a documented or known sensitivity to
medical adhesive products
Has dermatitis, burns, lesions, or tattoos at
or near the insertion site
Diaphoretic at the time of catheter
insertion
Requires application of topical antibiotics
or ointments under dressing






Has an IV site that requires a gauze pad or
a tackifier





Is pregnant
Requires a 14 or 16 gauge PIVC
Has a condition that in the opinion of the
investigator or staff nurse would make the
patient unsuitable for enrollment in this
study
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Once a patient was deemed eligible for participation, trained personnel in
obtaining informed consent approached him or her to invite participation. After informed
consent was obtained, participants were enrolled in the study. Participants were enrolled
Monday thru Friday, during the hours of 0800 to 1630. Patients were enrolled during
these hours due to additional resources being available to assist with obtaining consent as
well as administrative tasks, such as returning study documents to the PI.
Randomization
A convenience sample of patients was used. After patients were identified as
eligible for the study and informed consent obtained, the patient was randomly assigned
to one of the three PIVCs. The participants study group were determined randomly using
a six-sided dice from within the convenience sample of participants. Immediately after
obtaining consent, the PIVC inserting clinician rolled the dice to determine random
assignment. If the dice rolled a ‘1’ or a ‘2’, the patient received the open PIVC system 1.
If the dice rolled a ‘3’ or a ‘4’, the patient received the open PIVC system 2. If the dice
rolled a ‘5’ or a ‘6’, the patient received the closed PIVC system.
Insertion & Maintenance Procedures
PIVCs were inserted and maintained in accordance with guidelines from the
Infusion Nurses Society (INS) (2016) and the Centers for Disease Control and Prevention
(CDC, 2011). Clinicians inserting the study PIVC were trained and competencies
verified for inserting and maintaining each of the three types of PIVCs. Figure 2.
displays the enrollment and PIVC insertion process and was included as part of the
clinician training.
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Figure 2. Clinician workflow for patient enrollment in PIVC Nursing Research Study.
Clinical Training & Education of Participating Staff
Clinician training on the insertion technique for each device was provided in
addition to two weeks of practice in the clinical units/setting for each device (3 weeks
total) before beginning service as an inserting clinician. Training was provided at no cost
to the clinician (i.e., was scheduled during work hours with coverage for the time the
nurse spent away from the unit). The PI of the RCT was granted two awards, a $5,000
Research Fellowship and $2,000 Research Scholarship, which were to be utilized to
cover study expenses. The Chief Nurse Executive (CNE) approved the cost of clinician
training, and costs were absorbed by the monetary awards. To assist the individual units,
the internal scholarship money was available to assist with costs related to study supplies,
so that, products and supplies were not additional costs to units. Topics included in
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clinician training were adverse event reporting, PIVC insertion policy, consent process,
inclusion/exclusion criteria, PIVC data collection instruments, and hands-on return
demonstration training. Clinicians completed demographic information and were signed
off on review of policies, research design, and return demonstration for each of the
above-mentioned topics. Clinicians participating in the study were paid for their time,
and clinicians eligible for the hospital’s recognition program received nursing research
participatory points towards their clinical ladder portfolio.
Clinicians with experience and advanced skill, with regards to PIVC insertion,
were recruited from each of the study units (ED, Cancer Center, Treatment Center, and
Inpatient Nursing Units) and were invited to participate in the pilot study. Clinicians
were defined as registered nurses (RNs) or unlicensed ED Technicians and were required
to work a minimum of 20 hours per week. Enrollment was limited to day-time hours;
therefore, in order to enroll patients routinely, clinicians were required to work the dayshift and work a minimum number of hours.
Data Collection
Data was collected using paper questionnaires (see Appendix E and F) along with
data extraction from the EHR. Patient and Clinician Demographics that were collected
are listed in Table 2. Items collected using paper questionnaire are marked (P) and from
the EHR are marked (E). Clinician demographics were collected during the training
sessions for the nurses. All patient identifiers were removed from the database by the PI
for de-identification purposes before conducting analyses. A patient label was placed on
the consent form with a corresponding participant identification (ID) code. Thereafter,
only the participant ID code was used to label data collection tools. The list of patient
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identifier and corresponding ID codes was kept in a password protected excel spreadsheet
accessible only to the PI. The number of patients who refused consent was tracked for
reporting purposes only.
Table 2. Patient and Clinician Demographics
Patient Demographics










Hospital Status (i.e. Outpatient vs.
Inpatient) (E)
Age (E)
MR# (E)
Encounter # (E)
Gender (E)
Admitting Dx (E)
Principal Dx (E)
Secondary Dx's (E) (grouped by Dx
categories)
Location (department) of insertion (P)

Clinician Demographics


Working Area (Unit/Department) (P)





Years of IV Insertion Experience (P)
IV Team Member - Yes/No? (P)
RN, LPN, Tech (P)

Variables from the larger RCT were monitored for complete documentation in the
feasibility study, and included blood leakage during insertion, effectiveness of insertion
(number of attempts), complications (phlebitis, unplanned removal of PIVC, infiltration,
occlusion), dwell time, pain unrelated to above variables, pain during insertion, removal
reason, and cost will be collected electronically through the EHR. Variables collected
electronically (from EHR, represented by “E” in Table 2.) and observed for
completeness, included the following: blood leakage on insertion, insertion attempts,
complications (phlebitis, unplanned removal of PIVC, infiltration, occlusion), dwell time,
and removal reason. Variables collected manually (on paper, represented by “P” in Table
2.) and observed for completeness, included the following: insertion attempts, pain
unrelated to variables and pain during insertion, and cost. Appendix B depicts each
variable, its definition, and method of data collection (P) or (E). Missing data related to
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the above mentioned variables were evaluated by the PI and research team. Problems
identified with the completed documentation were discussed at the PIVC workgroup and
solutions were developed and communicated by the PI and research team. Any
recommended changes were discussed and considered for process adjustments.
Three PIVC products were used: the open PIVC system (18-24 gauge), and closed
PIVC system 1 and 2 (18-24 gauge). Potential add-ons used is shown in Table 3.
Table 3. Add On Products
Add-On Item #

Description

187006
178699
179277

7"Pressure Infusion Ext Set
Microbore Extension Set- 7 inch Non-DEHP
Microclave Clear

The clinician questionnaire (completed after PIVC insertion) (Appendix F) and
the patient questionnaire (completed after PIVC removal) (Appendix E) were collected
by and monitored by the PI for response rate and percentage of completed forms. These
questionnaires were created by adapting measures from the Emergency Care Research
Institute (ECRI), the CDC, and consulting content experts, including staff nurses and
quality and safety nurses. While no reliability and validity data exist for these measures,
two nurse experts verified the content validity.
Data Analysis
Outcomes collected for this pilot were clinician and patient questionnaire
response rate and percentage of completed questionnaires, number of missing data
elements and completed clinician training forms, thematic feedback from clinicians and
patients, enrollment participation, and preliminary costs. After data was collected from
secure boxes on inserting units, data was entered into an excel file and verified. Paper
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questionnaires were labeled with the participant’s unique participant ID code (not the
patient’s medical record number label) for tracking purposes and collected in a secure
lock box on each unit. Paper questionnaire data was transcribed and coded into an excel
file managed by and accessible only to the PI and specified members of the research
team. To reduce missing documents and data, the PI reviewed the enrolled participants
EHR documentation and the questionnaires daily and made efforts to collect missing
elements
EHR variables were extracted from the EHR for analysis using an internal
reporting system called Clarity Reporting. Data was deidentified by removing medical
record and encounter numbers prior to aggregation and analysis. Frequencies, descriptive
statistics, incidence rates, and skewed data was analyzed. Analysis that revealed findings
that suggested making a change to the study process were discussed and considered for
process adjustments. Understanding process related problems improved implementation
and expansion of this study at the other facilities. Any solutions, recommended changes,
or major structural problems requiring process change, affecting the IRB protocol itself,
necessitated obtaining appropriate permissions for IRB amendment approval, and were
updated through all appropriate IRBs.
Human Subjects Protection
IRB approval was obtained and patients were provided information explaining the
study. Consent was required and was obtained (Appendix C). Consent was provided by
onsite, trained personnel. While in the study, participants were at very low risk for
problems and were at no more risk than patients declining to participate in the study but
whom have a PIVC inserted. Any questions regarding participation in the study were
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answered prior to obtaining consent. If a patient declined to participate in the study, they
continued to receive standard PIVC care. All excel files were kept on a secure,
encrypted, password protected server accessible only to the PI. All protected health
information was maintained in strict confidence as required by law.
Results
Descriptive Analysis

Summaries of quantitative descriptive results are described in Table 4. Sixteen
(n=16) clinicians were trained for this pilot, which included inserting (n=9) and
consenting (n=7) roles. There was some overlap of roles, as some inserting clinicians
were also able to provide consent. Participant enrollment (n=35) over four weeks was
much lower than anticipated. Anticipated enrollment was to enroll 40 participants per
PIVC for a total enrollment of 120 participants. All participants that were agreeable to
participate in the study completed the consenting process. One subject declined to
participate after signing the consent form. There were a total of four (n=45)
complications during the pilot. Complications seen during the pilot included
unsuccessful insertion (n=1) and unplanned reinsertion (n=3).
Questionnaires were evaluated for percent returned (response rate) and percent
completed (missing data) as shown in Table 5. One challenge was unreturned patient
questionnaires (n=10), the highest contributing source of missing questionnaires. Of the
35 patient questionnaires distributed 10 (29%) were not returned. Of the patient
questionnaires returned, 100% were entirely complete with all questions answered. The
opposite problem occurred with clinician questionnaires. Clinician questionnaire
response rate was 100%; however, several returned questionnaires were incomplete.
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Table 6. displays the missing clinician and patient data from both the paper questionnaire
(1%) and the EHR data (4%).
Table 4. Quantitative Descriptive Results
(n)

(%)

Clinician Training (Total Clinicians 16)
Inserting
Consenting

16
9
7

56%
44%

Enrollment (Total Insertions 35)
Closed PIVC system 1
Closed PIVC system 2
Open PIVC system

35
9
19
7

26%
54%
20%

Complications (Total Insertions 35)
Unsuccessful Insertion
Unplanned Reinsertion

4
1
3

11.4%
2.8%
8.6%

(n)
35/35
25/35

(%)
100%
71%

Table 5. Questionnaire Response Rate
Clinicians
Patients

Table 6. Missing Data
Number Missing/Total
Missing Data - Clinicians
Paper Questionnaire
Did blood leak out of the catheter during or after
insertion?
Patient will go home with PIVC inserted?
EHR
Missing PIVC Study Type – not present in EHR
Missing Data - Patients
While the PIVC was in place, what was your average pain
level at the site of the PIVC?
What was your overall level of satisfaction with the PIVC?

(%)

2/35
2/35

5.7%
5.7%

6/35

17.1%

0

0%

0
0

0%
0%
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Content Analysis
Qualitative feedback was obtained through patient and clinician questionnaires.
These forms were collected by the PI and entered into an excel spreadsheet. Using
Graneheim & Lundman’s (2004) content analysis approach, feedback was broken down
into the simplest like-comments (meaning unit), which was then condensed and turned
into a code (p. 106-107). These codes were then grouped into similar categories as seen
in Table 7. The categories were reviewed and grouped into common themes, which
included closed PIVC system 1 Experience, closed PIVC system 2 Experience, open
PIVC system Experience, Enrollment, and Clinician Role. These themes were less useful
at identifying potential outcomes, but they were used to provide a framework for future
qualitative content analysis as the study progresses (Graneheim & Lundman, 2004; Hsieh
& Shannon, 2005).
PIVC Experience
Feedback for closed PIVC system 1included “more comfortable; placement is
more comfortable” (n=3). Participants enrolled appeared to prefer this PIVC (n=2), and
participants indicated it hurt less (n=4). Top closed PIVC system 2 feedback included
participants reporting easier insertion (n=6), less pain (n=6), and “more secure, least
complicated” in relation to device design (n=6). However, participants did indicate that
the closed PIVC system 2 required restart or reinsertion (n=6). Participants commenting
on the open PIVC system indicated that they observed bleeding (n=4), more pain (n=2),
and reinsertion needed (n=4). Reports indicating that open PIVC system was their least
favorite was also reported (n=3).
Enrollment

PIVC PILOT

22

The majority of the feedback from clinicians indicated that they experienced the
most difficulty in the pilot during the consenting process (n=9). Clinicians reported that
many patients declined to participate at the time of consent or that patients were
agreeable until the consent form was presented. Some clinicians reported other difficulty
during the consent process with participants feeling overwhelmed, fearful to sign, or
electing to not read the consent. Clinicians also reported insufficient numbers (n=7),
mostly with difficulty in recruiting appropriate participants that met inclusion/exclusion
criteria and that they found it difficult to complete the required paperwork.
Clinician Role
Patient feedback was overwhelmingly positive with regards to the staff working
with them during their treatment. Patients noted their positive feedback on staff
knowledge (n=12). Patients reported that “nurse medical advice has saved me pain and
discomfort” and that “nurses work to provide best care possible”. Staff reported that
staffing issues (n=6) such as time off, departmental changes, and job transitions affected
the clinician role in this pilot. Staff also felt that clinicians should be able to insert and
consent (n=5) to help with the staff availability issues causing delay in the consent
process (n=4). There was very little qualitative feedback from clinician training forms
evaluating the initial training sessions. As this was a pilot study, there were few
expectations about training and participating in the study. Clinicians provided no helpful
evaluative feedback on training sessions; rather, they focused their comments by
providing feedback in the clinician questionnaire.

PIVC PILOT

23

Table 7. Content Analysis-Clinician and Participant Enrollment Feedback
Themes

Categories

Closed PIVC system 1

Insertion 5
Hurts Less 4
Comfort 3
Device Design 3
Prefers PIVC 2

Closed PIVC system 2

Reinsertion 6
Hurts Less 6
Device Design 6
Easy Insertion 6
More Comfortable 2
Prefers PIVC 2
Difficult Insertion 1
Does not Prefer 1
Easier to Move 1
Difficult to Move 1

Open PIVC system

Bleeding 4
Reinsertion 4
Does not Prefer 3
Hurts More 2
Prefers PIVC 1
No Bleeding 1

Enrollment

Difficulty During Consent 9
Insufficient Numbers 7

Clinician Role

Staff Knowledge 12
Staffing Issues 6
Clinician Training 5
Staff Availability 4
Staff Professionalism 2

Cost Analysis
After initiating this pilot, two significant operational events occurred. The first
relates to the renegotiation of cost for the standard practice PIVC used, which led to a
reduction in cost of about $0.15 per product. A second operational event to occur was to
PIVC Start Kits. Each PIVC start kit had the surgical towel removed from the kit,
decreasing the cost by about $0.30 per product. The surgical towel had been previously
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used to help with the blood leakage reported on insertion. The surgical towel was
replaced by a lower quality, cheaper product. While these changes are minor, they
contribute to an overall reduction in cost and made analyzing cost between the three
PIVCs more difficult. These changes occurred after presentation to the Nurse Executive
Council in December 2015, but before beginning analysis of this pilot. Table 8. describes
what cost would have been if products costs would have remained steady throughout the
pilot. Product costs used in Table 7 are based on original figures provided by Materials
Management at the pilot site. Individual product costs were multiplied by products used
in the pilot to calculate total cost. Reinsertion costs were calculated based on a reported
unplanned removal of the study PIVC, and totaled the sum of a standard PIVC insertion
cost. Cost assumptions cannot be made using the pilot results; however, the framework
for calculating total and reinsertion costs were used to inform the larger RCT.
Table 8. Cost Analysis – Summary of pilot costs and products used
By Individual Product

Total Cost (USD)

Add ons
7” Pressure Infusion Extension Set ($1.85/product)
Microbore Extension Set – 7in Non-DEHP ($1.20/product)
Microclave ($0.80/product)

$7.40
$4.80
$27.20

PIVC
Closed PIVC system 1 ($2.53/product)
Closed PIVC system 2 ($3.69/product)
Open PIVC system ($1.50/product)

$22.77
$84.87
$13.50

Start Kit

$44.10

By PIVC Insertion
(Total cost of insertion, including Add-ons, PIVC, and Start Kit)
Closed PIVC system 1 Insertion

$41.31

Closed PIVC system 1 Insertion

$125.61

Open PIVC system Insertion

$37.93

By Reinsertion Costs
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Closed PIVC system 1 Insertion

$4.64

Closed PIVC system 2 Insertion

$9.28

Open PIVC system Insertion

$0.00
Implications

Resource Allocation
The largest insight this pilot revealed was the slower than expected enrollment.
Availability of inserting and consenting clinicians was part of the issue with slow
enrollment. It was anticipated that the ED would enroll the most participants, and for this
reason more inserting clinicians were trained in the ED than on inpatient units. However,
due to staffing changes and workflow barriers, the ED was unable to enroll any during
this pilot. The workflow in the ED prohibited the completion of additional consent form
and questionnaires, a barrier to enrollment. A future recommendation would be to
engage nursing leadership at the unit-level earlier in the designing phases to understand
unit-level concerns and resource allocation. The availability of consenting clinicians also
delayed the workflow for inserting clinicians. Ensuring at least two consenting clinicians
per participating unit would help reduce the waiting time for enrollment. In addition to
training more inserting clinicians, encouraging inserting clinicians to take human subjects
in research training to be able to consent should be considered for the expansion of this
study.
Missing Questionnaires
Missing patient questionnaires contributed to the largest category of missing
questionnaires. After speaking with bedside nursing, their knowledge of the pilot study
was limited. It was realized that communication to those participating in the study as
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well as organization leadership had occurred, but limited information was provided to
non-inserting and non-consenting front-line staff. Therefore, the importance of returning
the patient questionnaire was not communicated from shift to shift, and as a result not
returned to the PI. The PI established weekly rounding to reinforce the importance of
returning patient questionnaires. After enrollment of a participant, the consenting
clinician was also instructed to give verbal handoff to that subject’s nurse, also
reinforcing the importance of returning the patient questionnaire. To make the patient
questionnaire more visible in the room, the PI instructed participating clinicians to utilize
the whiteboard and magnets already present in the room. This kept the questionnaire
visible to both the enrollee and nursing staff.
Missing Data
EHR data contributed as the largest source of missing data. After drilling down
on the missing EHR data two things were determined regarding documentation. The first
was that staff were not documenting the PIVC in the PIVC Study Type flowsheet. The
clarity report was built to pull based on the presence of data in this field for all identified
inserting clinicians. When this field was left blank, no information would flow into the
clarity report, resulting in the need for manual abstraction. The second thing identified
was that even when this field had correct documentation present, if the inserting clinician
was not the one to document, no information would flow into the clarity report. It came
to the team’s attention that clinicians not identified as an inserting clinician for the study
would assist the inserting clinicians by documenting for them. The clarity report was
built to pull information documented by the inserting clinicians in the study only.
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Education and awareness was quickly provided to the staff and participating clinicians on
the importance of accurate documentation by inserting clinicians only.
Informing the Larger RCT
The results from this pilot have informed and provided recommended changes to
the larger RCT and are summarized in Table 9. Understanding the workflow, process,
and needed resources has revealed clearer expectations for the continuation and
expansion of the study. After analyzing the pace of enrollment and resources needed,
recommendations for additional inpatient clinicians to be trained in both insertion and
consenting was identified. Strategically placing consenting clinicians will be important
for ease of enrollment. Furthermore, recognizing the unit-level resource limitations will
help to identify appropriate enrollment locations.

Lastly, the work done to establish a

framework for future content analysis was developed as a result of this pilot.
Table 9. Lessons Learned and Clinical Implications
Lessons
Learned
Slower than
expected
enrollment
Few returned
Patient
Questionnaires
Pilot informed
recommended
changes for
larger RCT

Clinical Implications
 Second training arranged to engage more clinicians
 Every 36-bed unit should train (2) inserting clinicians and (1)
consenting clinician
 Utilize patient room whiteboards and magnets to increase returned
documents
 Weekly rounding to reinforce importance of returned documents
 Framework for future Content Analysis was developed
 Avoid areas where consent process may delay care
 Engage with leadership in planning phase to help with communication
and resource allocation
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Strengths and Limitations
This pilot used the PDSA cycle as the guiding framework for study
implementation. Using this process was a practical way of determining the feasibility of
such a large study design in the context of a complex organizational structure. The study
design for the larger RCT is the first of its kind; therefore, this pilot has positively
informed the continuation and expansion of the larger RCT. The lessons learned and
analysis from this pilot provides a framework for future data analysis.
This pilot was limited to four weeks of data collection, which may not have been
enough time to truly understand all of the barriers and processes needing improvement.
With a slower than expected enrollment rate and low participation from units involved, a
longer time period for the pilot may have been beneficial. Another limitation to this pilot
is the shifting and renegotiation of prices for products used within the study. Obtaining
pricing information, along with renegotiated cost/product across the healthcare system,
has caused considerable difficulty in completing a cost analysis.
Conclusion
The pilot of a RCT comparing outcomes of three different PIVCs was
successfully completed and has constructively informed the larger RCT. The PDSA
cycle is an effective guiding framework to understand the process for implementing the
larger RCT study design. The steps in the PDSA cycle provided structure to the PI to
plan, implement, analyze, and act upon the proposed study. The pilot results suggest that
enrollment to this study is slow due to limited availability of consenting clinicians and
that resource allocation, in general, is a barrier to this study. Enrollment is not feasible in
areas where workflow is time sensitive and pace of work cannot accommodate a delay in
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patient care. While results from this pilot were limited to identification of process
improvement opportunities, the results of this pilot suggest that there is need for
continued enrollment, because it is still unclear which PIVC is best in terms of
complications, satisfaction, and cost. The recommendation from this pilot study will be
to continue enrollment at the pilot site and to expand to the other proposed hospitals,
building on lessons learned from the pilot.
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Appendix A – Add on Products
Table 3. Add on Products
Add-On Item # Description
187006
178699
179277

7"Pressure Infusion Ext Set
Microbore Extension Set- 7 inch Non-DEHP
Microclave Clear
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Appendix B – Data Glossary
Term

Definition

Measurement
Definitions

Add-Ons (P)

Per INS Standards of Practice (2016), adds on are defined as devices that
minimize manipulation and reduce multiple components, such as single and
multi-lumen extension sets and/or needleless connectors (INS, 2016). Addons should be considered only for clinical indications (INS, 2016).

Used at time of
insertion.

Adverse Event

According to the Sentara Healthcare (SHC) Incident and Event Reporting
Risk Management Policy, any event unrelated to the ordinary course of the
patient’s hospitalization, will be reported according to SHC policy.

Incident and
Event
Reporting SHC
Policy (5/2015)

Adverse Event
(Serious)

As defined by the pilot facility’s IRB, Serious Adverse Events include any
experience that is fatal or life threatening, is permanently or significantly
disabling, requires inpatient hospitalization or prolongation of
hospitalization, a congenital anomaly/birth defect or is medically
significant. Adverse events related to this study are to be reported to the
IRB, according to IRB policy.

Institutional
Review Board

Closed PIVC
system 1

Closed PIVC System without stabilization, available in 18-24 gauge;
however, is not power injectable and has no large bore catheter available.

N/A

Open PIVC
system

Open PIVC System without stabilization, available in 14-24 gauge, and has
power injectable capability and a large bore catheter is available.

N/A

Closed PIVC
system 2

Closed PIVC System with built-in stabilization, available in 18-24 gauge,
and has power injectable capability (with exception of 24 gauge), but has
no large bore catheter available.

N/A

Blood exposure
(E)

"Occupational exposure to blood borne pathogens related to leakage, spill,
2016 INS
or splash of blood through needlesticks or cuts from other sharp instruments
Policies &
contaminated with an infected patient's blood or through contact of the eye,
Procedures
nose, mouth, or skin with a patient's blood"11.

Blood leakage
(P)

Blood leakage will be defined as blood leaking from the catheter onto an
area unexpectedly. For example, blood leaking onto intact skin, staff
clothing, bed linen, or patient clothing would be considered blood leakage.

Clinician

Registered Nurse (RN), Licensed Practical Nurse (LPN), or Technician.

Closed System

Closed systems are PIVCs that may not require add ons during the insertion
process. The add ons and PIVC are one product, and come packaged as
one unit together.
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Term

Definition

Measurement
Definitions

Data Safety
Monitoring
Process

According to the Sentara Healthcare (SHC) Incident and Event Reporting
Risk Management Policy, any event unrelated to the ordinary course of the
patient’s hospitalization, will be reported according to SHC policy.
According to the policy, incident reporting is not a part of the medical
record, and is not to contain information related to the hospitalization or
treatment of any patient in the ordinary course of hospitalization of such
patient. Staff members with the best first-hand knowledge of what
occurred should complete an incident and event report, according to policy
and job aides. Investigation will be initiated, as appropriate, within 24
hours of receipt of the incident/event report, or notification of the event.

Incident and
Event
Reporting SHC
Policy (5/2015)

Diaphoretic

Profuse sweating, which may interfere with the adhesion of study PIVC
dressings.

Dwell time (E)

The amount of time a catheter is dwelling in the vein (INS, 2016).
Recommendation from INS (2016) is a dwell time no longer than 96 hours.

Measured in
Hours

Infiltration (E)

Inadvertent administration of a nonvesicant solution or medication into
surrounding tissue (INS, 2016). Infiltration will be classified according to
the INS, as follows: 0, no symptoms/signs; 1+, skin blanched, edema <1
inch, cool to touch, with or without pain; 2+, skin blanched, edema 1-6
inches, cool to touch, with or without pain; 3+, skin blanched/translucent,
gross edema >6 inches, cold to touch, mild-moderate pain, possible
numbness; and 4+, skin blanched, translucent, skin tight/leaking/discolored,
bruised, swollen, gross edema >6 inches, deep pitting tissue edema,
circulatory impairment, moderate-severe pain, infiltration of any amount of
blood product, irritant, or vesicant (INS, 2016; INS, 2006).

2016 INS
Policies &
Procedures;
2006 INS
Standards of
Practice

Informed
Consent

Informed consent is required for human subject participation in research
according to federal rules and regulations (INS, 2016).

N/A

Inpatient
Population (E)

Inpatient is defined as an inpatient admission to an inpatient unit.

Point of Entry

Occlusion (E)

The inability to flush the catheter without resistance and the inability to
yield a blood return (INS, 2016).

2016 INS
Policies &
Procedures

Open System

Open systems are PIVCs that require add ons to be added as part of the
insertion process. The add ons and PIVC are separate products, and do not
come packaged together.

Outpatient
Population (E)

Outpatient is defined as patients being treated in the Treatment Center,
Cancer Center, ED, or designated as Observation Status.

Point of Entry
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Measurement
Definitions

Term

Definition

Pain: during
insertion (P)

Standard Analog Scale 0-10 Scale or Wong Faces Scale

Pain: unrelated
complication
variables (P)

Standard Analog Scale 0-10 Scale or Wong Faces Scale

Patient
Identifiers (E)

Patient identifying information, which may include age, gender, or visit
number.

Patient
Satisfaction (P)

Satisfaction with the insertion process; evaluation of insertion and dwell
time.

Phlebitis (E)

Mechanical causes of phlebitis result in vein wall irritation can be caused
by multiple manipulations of infusion delivery system, large catheter gauge
size, catheter material and diameter, failure to stabilize catheter adequately,
failure to stabilize the joint if insertion site in or near a joint must be used.
Signs and symptoms of phlebitis include pain/tenderness at site, erythema,
warmth, swelling, induration, purulent drainage, palpable venous cord
(INS, 2016). Phlebitis will be classified according to the INS, as follows: 0,
no symptoms/signs; 1+, redness with/without pain; 2+, redness and/or
swelling accompanied with pain; and 3+, redness and/or swelling
accompanied with pain (INS, 2016).

Phlebitis
Classification
Scale; 2016
INS Policies &
Procedures

Unplanned
Removal of
PIVC (E)

Early removal of catheter unrelated to treatment plan (INS, 2016)

2016 INS
Policies &
Procedures
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Appendix C – Informed Consent
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Appendix D – Patient & Clinician Demographics
Table 2. Patient and Clinician Demographics
Patient Demographics
▪ Hospital Status (i.e. Outpatient vs.
Inpatient) (E)
▪ Age (E)
▪ MR# (E)
▪ Encounter # (E)
▪ Gender (E)
▪ Admitting Dx (E)
▪ Principal Dx (E)
▪ Secondary Dx's (E) (grouped by Dx
categories)
▪ Location (department) of insertion (P)

Clinician Demographics
▪

Working Area (Unit/Department) (P)

▪
▪
▪

Years of IV Insertion Experience (P)
IV Team Member - Yes/No? (P)
RN, LPN, Tech (P)
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Appendix E – Patient Questionnaire
Completed after removal, up to a week to obtain
PIVC Study – Patient Questionnaire
Instructions: After the study peripheral intravenous catheter (PIVC) is removed, please mark
your evaluation of the study PIVC below.
1. While the PIVC was in place, what was your average pain level at the site of the PIVC?
Circle the number on the scale where 0 is no pain and 10 is the worst pain you can imagine.
0
1
2
3
4
5
6
7
8
9
10
No
Severe
Pain
Pain
2. What was your overall level of satisfaction with the PIVC?
1-2
3
4
5
6
7
Extremely
dissatisfie
d
3. Comments:

8

9

10 –
Extremely
satisfied
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Appendix F –Clinician Questionnaire (Front Side)
PIVC Study – Clinician Questionnaire
Completion of this questionnaire implies voluntary participation in the PIVC study and
informed consent. Your personal information will not be linked with this questionnaire.
Insertion Date: ____________
Insertion Time:_________________
Insertion Facility: ☐SRMH ☐ SMJH ☐SCH
How many insertion attempts for success? 1
2
3
4
5
other:_______
How many staff attempted insertion?
1
2
3
Did blood leak out of the catheter during or after insertion?
Yes No
Blood leaked onto:☐ Patient ☐ Staff ☐ Patient clothing ☐ Staff clothing ☐ Bed Linen
☐Other:____
Cleaning supplies used: ☐ Additional Gauze ☐ Linen Towel ☐Disinfectant wipe
☐Other:____
Patient will go home with PIVC inserted: ☐Yes ☐ No
What was the patient’s pain rating during insertion?
Circle the number on the scale where 0 is no pain and 10 is the worst pain imaginable.
0
1
2
3
4
5
6
7
8
9
10
No
Severe
Pain
Pain
Insertion Questions

Disagree…………………………….Agree

The flashback visualization was effective in assisting
with insertion
Sharpness of needle is acceptable
The catheter threads easily without kinking or bending
The device is easy to use and does not affect my ability
to start IV
The needle safety feature operates reliably
The use of this product requires you to use the needle
safety feature
The product stops the flow of blood after the needle is
removed
The user does not have to wipe blood from the patient’s
skin surface surrounding IV site after insertion
The user does not need extensive training for the
product to be operated correctly
Patient discomfort is not increased with use of this
catheter

1

2

3

4

5

Additional comments:
Participant’s ID Code - Label
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Appendix F –Clinician Questionnaire (Back Side)
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Appendix G –Clinician Training
PIVC Study – Clinician Training
Completion of this training implies voluntary participation in the PIVC study and
informed consent. Your personal information will not be linked with this questionnaire.
Years of IV Insertion Experience:
< 1 year 1-3 years 3-6 years 6-10 years

> 10 years

Please check the box next to your primary working unit:
ED Treatment Center Cancer Center Inpatient Nursing Unit
Are you a member of the IV Therapy Team? Yes No
On a scale from 1 to 10, 1 being very low self-confidence with the skill of inserting
PIVCs, and 10 being very high self-confidence with inserting PIVCs, where would you
rate yourself today? (circle one)
1
2
3
4
5
6
7
8
9
10
Low self-confidence
High self-confidence
Training Topics
Reporting Adverse Events
PIVC Insertion Policy
Consent Process
Inclusion / Exclusion Criteria
PIVC Study Data Collection
Instruments
Onsite PIVC Training

Review of Policy
Completed

Return Demonstration
Completed

Appendix H – Conceptual Model
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Appendix I – Table of Evidence – Systematic Review

Table 1. Table of Evidence - Open vs. Closed Peripheral Intravenous Catheter Systems
Author
(Year)

Research
Design

Level of
Evidence*

Sample and
Sample Size

BausoneGazda, D.
(2010)

RCT

II

Convenience Sample
collected from 302
medical-surgical
patients from 9/200812/2009, by VAD
RNs in a Level 1
Trauma Magnet
Designated Facility.

Investigational Group
(n=150) and control
group (n=152)

IRB approval
obtained, and written
informed consent
obtained from study
participants.

Intervention

Instruments

Results/Stats Evidence

Summary/ Conclusion

Subjects were
randomly placed
into the control
group (receiving
the nonwinged B.
Braun Introcan
Safety Catheter
without built-in
stabilization) or the
investigational
group (receiving
the BD Nexiva
Closed IV Catheter
System with built
in stabilization).

Control catheter Nonwinged B.
Braun Introcan
Safety Catheter

Investigational catheter
significantly noninferior
to the control catheter.
Cox Regression Model
HR 0.740 (90% CI:
0.530-1.034)

Investigational
catheter – BD
Nexiva Closed IV
Catheter System

Reducing complications
by 26% when using the
investigational catheter.

With regards to
stabilization, the
investigational catheter
reduced stabilization-related
complications by 26%, and
was as effective, if not more
so, in terms of locationrelated complications, than
the control catheter.
Furthermore, Nurse
satisfaction significantly
increased with use of the
investigational catheter.
Findings support INS
recommendation to use a
catheter including a
stabilization platform with
dressing designed for
stabilization.

Nurse satisfaction
significantly improved
with the use of the
investigational catheter
(56% compared to 36%,
P≤ 0.001).

Randomization was
computer
generated.

Statistical Method:
Cox Regression Analysis

Gonzalez
Lopez, J.L.
et al, (2013)

Prospective
RCT

II

952 catheters (513
inpatients) - all
patients ≥ 18
receiving PIVC at

PIVCs inserted and
maintained in
accordance with
CDC guidelines.

Compact closed
System Catheter
(COS) – BD Nexvia

Results:
Using COS PIVCs
provides a RRR of 29%

With use of the COS
PIVCs, indwell times were
significantly longer with
phlebitis and infiltration
Continued on next page
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Sample and
Sample Size
one of three wards in
Madrid, Spain
between March and
July 2008; target
sample was 1200
catheters to evaluate.

126 nurses on the
three wards
comprised the field
researchers.

Written informed
consent obtained
from study
participants.

Intervention
Both PIVCs were
examined for
effectiveness,
efficacy, safety,
and efficiency.
Dwell time and
complication rates
were collected for
evaluation.
Randomization was
computer
generated.

Instruments

Mounted open
System Catheter
(MOS) – B. Braun
Vasocan Safety
Catheter

Results/Stats Evidence

Summary/ Conclusion

of CRC compared to
MOS PIVCs (CI 95%;
p<0.001)

rates being simultaneously,
significantly lower. While
ease of use of the MOS
PIVCs was of significance,
attributed to nurses being
familiar with the MOS
system, less COS PIVCs
needed to be removed due
to CRC. Overall total
complications were less in
the COS PIVCs group, than
the MOS PIVCs group,
indicating fewer
complications from the
closed catheter group versus
the open catheter group.

MOS and COS PIVCs
received no needle stick
injuries during the study,
proving that both are
passive safety devices.

Median time for indwell
times before adverse
event was significantly
higher for COS group
than the MOS group
(P=0.003)

Significant reduction in
phlebitis rates of 29%
(P=0.004) when using
COS PIVCs.

Total complications of
COS PIVCs per 1000
catheter-days (109.87)
was significantly lower
than the MOS PIVCs per
Continued on next page
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Sample and
Sample Size

Intervention

Instruments

Results/Stats Evidence

Summary/ Conclusion

100 catheter-days
(135.57) (P<0,001).

Statistical Methods:
Qualitative Variables
analyzed using Chi
Square or Fisher’s Exact
Tests
Quantitative Variables
analyzed using student’s
t-test.

Richardson,
D. et al,
(2011)

NonExperimental
; Qualitative

VI

104 nurses were
recruited through
telephone interviews
and placed intone of
two groups, based on
SPIVC used at their
facility.

Online survey
conducted with
Purchasing Agents
and Materials
Managers

Telephone
Interviews
conducted with
nurses and nurse
managers. Nurses
recruited were
placed into either
Traditional SPIVC
(open) or Blood-


Online
Survey

Telephone
Interview

Qualitative Results:
49% of nurse respondents
using traditional SPIVCs
indicated blood exposure
50% of the time

Nurses that use bloodcontained SPIVC are less
likely to experience blood
exposures, if at all.

89% of nurse respondents
using blood-contained
SPIVCs indicated no
blood exposure 89% of
the time.

Continued on next page
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Catheters:

Results:

Variable CICS – BD
Nexiva Catheter

Restart rates were
significantly lower in the
CICS group, than with the
traditional catheter
(open).

There are no significant
differences in incidence
rates of adverse events
between CICS and
traditional catheters;
however, restart rates are
significantly lower in the
CICS group. CICS wingshaped stabilization
platform was considered a
contributing factor for the
reason replacement rates
were lower in the CICS
group.

contained SPIVC
(closed) groups and
their telephone
interview data was
aggregated.

Tamura, N.
et al, (2014)

SemiRandom
Control Trial

II

359-Patients ≥ 20
years old, needing
PIV for more than 72
hours.

Exclusion criteria:
pregnant women,
skin inflammation,
burns, lesions, or
tattoos near the
insertion site, patients
receiving anticancer
therapy, patients with
limited insertion
sites, and those
requiring specialized
dressings.
Written informed
consent obtained
from study
participants.

Patients were
divided into two
groups to receive
the CICS (n=194)
or traditional
catheter (open)
(n=165), according
to study month.
i.e. patients
enrolled in months
1, 3, and 5 received
the CICS; those
enrolled in months
2, 4, and 6 received
the conventional
catheter.

Conventional
catheter – Medikit
Company

Objective
observations and use
of INS 4-point scale,
recommended for
Phlebitis
classification.

Reason for removal

Bending/Kinking
(p=0.0060)

Displacement/Lo
osening of the fixation
site (p=0.0060)

Extravasation
(p=0.009)
Statistical Methods:

Nurses were
trained in use of
CICS and were
required to
successfully use the
CICS in at least

Descriptive Statistics

This study supports using
CICS to meet the CDC and
INS recommendations.

Fisher’s Exact Test
Kaplan-Meier Analysis

Continued on next page
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five patients prior
to start of the study.
CDC= Centers for Disease Control; CI= Confidence Interval; CICS= closed intravenous catheter system; COS= Closed System; COSMOS=
Closed System/Open System Study; CRC= Catheter-related Complications; ED= Emergency Room; HR= Hazard Ratio; INS= Infusion Nurses
Society; MOS= Open System; OR= Operating Room; PIVC= Peripheral intravenous catheter; PIV= Peripheral intravenous catheter; PPS= per
protocol set; RCT= Randomized Controlled Trial; RRR= Relative Risk Reduction; SPIVC= short traditional intravenous catheter; VAD=
Venous Access device
*Melnyk and Fineout-Overholt [3] used to determine level of evidence
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